Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study

OBJECTIVES: To assess the long-term safety and efficacy of the Janus kinase inhibitor upadacitinib versus adalimumab over 3 years in the ongoing long-term extension (LTE) of SELECT-COMPARE, a randomised controlled phase 3 trial of patients with active rheumatoid arthritis and inadequate response to...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Roy, Mysler, Eduardo, Bessette, Louis, Peterfy, Charles G, Durez, Patrick, Tanaka, Yoshiya, Swierkot, Jerzy, Khan, Nasser, Bu, Xianwei, Li, Yihan, Song, In-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819784/
https://www.ncbi.nlm.nih.gov/pubmed/35121639
http://dx.doi.org/10.1136/rmdopen-2021-002012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819784/
https://www.ncbi.nlm.nih.gov/pubmed/35121639
http://dx.doi.org/10.1136/rmdopen-2021-002012

Ejemplares similares